20S proteasome catalytic subunits (beta 5, beta 1, and beta 1i) (PSMB5/PSMB6/PSMB9)

The 20S proteasome is the central proteolytic core of the ubiquitin-proteasome system, responsible for the degradation of intracellular proteins. It is composed of four heptameric rings, with the inner beta rings containing the catalytic subunits: beta 5 (PSMB5), which exhibits chymotrypsin-like activity; beta 1 (PSMB6), which exhibits caspase-like activity; and the inducible beta 1i (PSMB9/LMP2), which replaces beta 1 in the immunoproteasome to enhance antigen processing [UniProt P28074, P28066, P28065]. These subunits are critical therapeutic targets in oncology, particularly for plasma cell dyscrasias like multiple myeloma, where high protein synthesis rates make cells hypersensitive to proteasome inhibition [PubMed 21685910]. Drugs like bortezomib and carfilzomib bind to the N-terminal threonine residues of these subunits, blocking their enzymatic function and leading to the accumulation of misfolded proteins and the induction of apoptosis [DrugBank DB00188]. While highly effective, targeting these subunits can cause significant side effects, including peripheral neuropathy and myelosuppression, due to the essential role of the proteasome in normal cellular maintenance [StatPearls, Proteasome Inhibitors].

Other names

Proteasome subunit beta type-5Proteasome subunit beta type-6Proteasome subunit beta type-9LMP2Large multifunctional protease 2PSMB5PSMB6PSMB9MacropainMulticatalytic endopeptidase complex

Inhibition of the N-terminal threonine residue within the catalytic subunits of the 20S proteasome, preventing the degradation of polyubiquitinated proteins and inducing the unfolded protein response and apoptosis.